activated recombinant human factor VII
activated recombinant human factor VII is a pharmaceutical drug with 34 clinical trials. Historical success rate of 93.8%.
Success Metrics
Based on 30 completed trials
Phase Distribution
Phase Distribution
6
Early Stage
15
Mid Stage
4
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
88.2%
30 of 34 finished
11.8%
4 ended early
0
trials recruiting
34
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery
Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury
Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation
Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Clinical Trials (34)
Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery
Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury
Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation
Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial Hepatectomy
Use of NovoSeven® in Active Variceal Bleeding
Safety and Efficacy of Activated Recombinant Human Factor VII in Patients Undergoing Orthotopic Liver Transplantation
Activated Recombinant Human Factor VII in Pelvic-acetabular Fracture Reconstruction
Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage
Safety and Tolerability of Intravenous Doses of Activated Recombinant Human Factor VII in Healthy Volunteers
Efficacy and Safety of Activated Recombinant Human Factor VII in Severely Injured Trauma Patients
Activated Recombinant Human Factor VII Following Cardiac Bypass Surgery for Paediatric Congenital Heart Disease
Dose Response to Recombinant Factor VIIa When Administered for Bleed
Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State
Safety and Preliminary Efficacy of Recombinant Activated Factor VII in Subjects With Traumatic Brain Injury
High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors
Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia
Treatment of Congenital Factor VII Deficiency
Use of Activated Recombinant Human Factor VII in Cardiac Surgery
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 34